You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 253 No. 10, March 8, 1985 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (50)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Comparative Study of Ceftriaxone and Spectinomycin for Treatment of Pharyngeal and Anorectal Gonorrhea

Franklyn N. Judson, MD; Josephine M. Ehret; H. Hunter Handsfield, MD

JAMA. 1985;253(10):1417-1419.


Abstract

Of the currently recommended regimens for treatment of uncomplicated gonorrhea, only aqueous penicillin G procaine is effective against infections at all sites. However, procaine penicillin is not effective against penicillinase-producing Neisseria gonorrhoeae and suffers from poor patient acceptability owing to the 10-mL volume of injection and allergic and toxic procaine reactions. Ceftriaxone is a new extended-spectrum cephalosporin with a long serum half-life and is many times more active than penicillin G against both β-lactamase—positive or —negative strains of N gonorrhoeae. Ceftriaxone was compared as a single, 125-mg, 0.5-mL injection with a single 2-g injection of spectinomycin in difficult to treat pharyngeal gonorrhea in men and women and anorectal gonorrhea of men. Ceftriaxone cured 30/32 (94%) pharyngeal and 52/52 anorectal infections, compared with 6/14 (43%) and 9/9, respectively, for spectinomycin. Both regimens were well tolerated. Ceftriaxone may prove to be a drug of choice for uncomplicated gonorrhea, particularly where homosexual men are treated and/or penicillinase-producing N gonorrhoeae is prevalent.

(JAMA 1985;253:1417-1419)



Author Affiliations

From the Disease Control Service, Denver Department of Health and Hospitals (Dr Judson and Ms Ehret), the Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center (Dr Judson), Denver; the Seattle-King County Department of Public Health, and the Department of Medicine, University of Washington School of Medicine, Seattle (Dr Hands-field).


Footnotes

Reprint requests to Disease Control Service, 605 Bannock St, Denver, CO 80204-4507 (Dr Judson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Antibiotic-Resistant Neisseria gonorrhoeae
Judson
ANN INTERN MED 1989;110:5-7.
ABSTRACT  

Epidemiology and Treatment of Oropharyngeal Gonorrhea
HUTT and JUDSON
ANN INTERN MED 1986;104:655-658.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.